RxDoctor Payments Data

Kristyn Caldwell

Family · Fairmont, WVNPI 1841762341

Payments from drug & device makers

$1,948in general payments, 2019–2025

Across 90 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Osprey Medical Inc$428
  • AstraZeneca$309
  • Johnson & Johnson$303
  • Pfizer$285
  • Novartis$232
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$174
  • plus $218 from 5 others

What the payments were for

  • Food & beverage$1,948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,948 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$29,950
Medicare patients
328
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban475$460,977
XareltoRivaroxaban174$178,060
EntrestoSacubitril/Valsartan72$83,237
Repatha SureclickEvolocumab114$69,812
BrilintaTicagrelor31$28,187
JardianceEmpagliflozin14$24,431
Praluent PenAlirocumab21$11,626
Metoprolol Succinate828$10,396
Ranolazine ErRanolazine122$8,960
Diltiazem 24hr Er (Cd)Diltiazem Hcl229$4,864
Atorvastatin Calcium434$3,685
Isosorbide Mononitrate ErIsosorbide Mononitrate288$2,836
Amlodipine Besylate498$2,492
Flecainide Acetate86$2,368
Losartan Potassium269$2,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$285$460,977475 claims
Johnson & JohnsonXarelto$303$178,060174 claims
NovartisEntresto$232$83,23772 claims
AstraZenecaBrilinta$309$28,18731 claims
Boehringer IngelheimJardiance$22$24,43114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.

Other family in Fairmont

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →